The purposes of this study were to determine the effects of ovarian hormone removal on force-generating capacities and contractile proteins in soleus and extensor digitorum longus (EDL) muscles of mature female mice. Six-month-old female C57BL/6 mice were randomly assigned to either an ovariectomized (OVX, n=13) or a sham-operated (sham, n=13) group. In vitro contractile function of soleus and EDL muscles were determined 60-d post-surgery. Total protein and contractile protein contents were quantified and electron paramagnetic resonance (EPR) spectroscopy was used to determine myosin structural distribution during contraction.
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In vitro muscle preparation
The soleus muscle from one hindlimb and the EDL muscle from the contralateral hindlimb of each mouse were studied to determine muscle contractile function and how that function was altered by the loss of ovarian hormones. The isolated mouse muscle preparation used was similar to that described previously (33). After a muscle was excised, it was mounted in a 0.38-ml bath assembly filled with Krebs-Ringer bicarbonate buffer maintained at 25˚ C by a recirculating water bath. The proximal tendon was attached by 6-0 silk suture to a dual-mode muscle lever system (300B-LR; Aurora Scientific Inc., Aurora, ON, Canada). Muscles were set to their anatomic L o (i.e., a length halfway between the muscle's minimum and maximum in vivo lengths) which coincides with the length at which isometric twitch forces are maximized (32).
All contractile measurements began at L o .
Muscles remained quiescent for 10 min in the bath assembly and then a protocol for testing contractile function began. First, passive stiffness of the inactive muscle was determined by passively stretching the muscle sinusoidally from 97.5% L o to 102.5% L o at 0.5 Hz while measuring the resulting force (33, 34). Thirty seconds later peak twitch force was elicited by stimulating the muscle with a 0.5-ms pulse at 150 V (Grass S48 stimulator delivered through a SIU5D stimulus isolation unit; Grass Telefactor, Warwick, RI). A second twitch was elicited 30 s later. Maximal isometric tetanic contraction force (P o ) was next elicited by stimulating muscles at 150 V and 400 ms at 120 Hz for soleus muscles and 200 ms at 180 Hz for EDL muscles. Two minutes later, a second maximal isometric tetanic contraction was elicited and at peak force a sinusoidal oscillation of 0.01% L o at 500 Hz was imposed to determine active muscle stiffness.
Last, twelve shortening velocities were measured by quick releases from P o to given afterloads that corresponded to 5-50% of the previous P o. Maximal shortening velocity (V max ) was Ovarian hormone effects on muscle contractility and myosin JAP-01029-2005. R1 7 determined by fitting a hyperbolic-linear curve to the force-velocity data Table Curve 2D (version 5.1, Systat Software Inc, Richmond CA) and extrapolating the curve to a zero afterload (32). Maximal power output by each muscle was calculated from force-velocity data using the non-linear curve-fitting procedures in the application Math Cad (version 12, Cambridge, MA).
The stimulator and lever system were controlled by computer (Pentium 4, 3.2 GHz) using a KPCI-3108 interface board (Keithley Instruments; Cleveland, OH) and TestPoint software (version 5, Capital Equipment; Billerica, MA).
Muscles were removed from the bath assembly at the end of the contractile protocol, trimmed, blotted, weighed, and then immediately frozen in liquid nitrogen and stored at -80 o C for subsequent protein analyses. Muscle weight and length data, using a fiber length-to-muscle length ratio of 0.71 for soleus muscle and 0.44 for EDL muscle, were used to calculate physiological cross-sectional area (2, 33).
EPR Spectroscopy
EDL muscles that were not used for the in vitro contractile analyses from each mouse were glycerinated for 3 d as described previously (19, 20) and then stored in a 50% glycerolrigor buffer for 1-5 mo. Permeabilized EDL muscles were dissected into fiber bundles that were ~0.5 mm in diameter and had fibers running in parallel from end to end. These fiber bundles were prepared for EPR spectroscopy by spin labeling with 0.5 mM 4-(2-idoacetamido)-2,2,6,6-tetramethyl-1-piperidinyloxy spin label (IASL; Sigma) specifically at the Cys 707 (SH1) in the catalytic domain of the myosin head (19, 20) . IASL-labeled fibers were fixed in a glass capillary tube inside a TE 102 cavity (4102ST/8838; Bruker Instruments, Billerica, MA) so that the longitudinal axis of the fibers was perpendicular to the magnetic field. Buffers were flowed over Ovarian hormone effects on muscle contractility and myosin JAP-01029-2005.R1 8 the fibers at a rate of 2 ml/min at 22 o C. For each fiber bundle, EPR spectra were collected under conditions of rigor, relaxation and contraction on an E500 EleXsys spectrometer (Bruker Instruments). The parameters used to collect the low-field portion of the EPR spectrum were 3415 gauss central peak, 15 gauss sweep width, 5.0 gauss peak-to-peak modulation amplitude, and 15.9 mW microwave power. Spectra were analyzed to determine the fraction of myosin strongly bound to actin during contraction as previously described (19, 20) . Two to three bundles from each EDL muscle were analyzed and their values averaged to represent the fraction of myosin bound to actin during contraction for that muscle.
During spectroscopy, one end of the permeabilized fiber bundle was attached to a force transducer (SensoNor Ackers 801 strain gauge; Aksjelskapet, Norway) and the other end stabilized to hold the fibers isometrically. Thus, force was monitored throughout EPR spectra collection. Maximal Ca
2+
-activated force of each fiber bundle was normalized to contractile protein content divided by fiber bundle length. This was necessary as bundle cross-sectional area could not be accurately calculated because bundles were not uniformly shaped, i.e., the crosssection of some bundles appeared circular while other bundles were more strip-like. The contractile protein content of each EPR sample was determined by gel electrophoresis as described below.
Determination of total, MHC, and actin protein contents
Each soleus and EDL muscle from the in vitro contractile analysis was homogenized in 10 mM phosphate buffer (pH 7.0) and assayed in triplicate for total protein content using BCA were run on each gel ( Figure 1 ). Purified MHC was a kind gift from the laboratory of David D.
Thomas and actin was purchased from Sigma (A2522). Soleus and EDL muscle samples were run on separate gels.
EDL fiber bundle samples from the EPR experiments were also assessed for myosin and actin contents. Following EPR, fiber bundles were stored in Laemmli sample buffer containing ß-mercaptoethanol at -80˚ C. Immediately prior to electrophoresis, EPR samples were heated to 100 ˚C for 5 min. Quantitative gel electrophoresis was performed on 20 µl of each EPR sample similar to the procedure for whole muscle homogenates.
All gels were stained for 1 hr with 0.1% Coomassie Blue R-250, 30% methanol and 10% glacial acetic acid, and destained overnight in 20% methanol and 10% glacial acetic acid.
Stained gels were scanned using a Bio-Rad GS-700 imaging densitometer and analyzed using 
Results

Body mass, muscle mass, and protein contents
The removal of ovarian hormones for 60 d caused increases in body and muscle masses.
Body mass for OVX mice was 13% greater than for sham mice (27.3 ± 3.9 vs. 23.9 ± 2.4 g; P = 0.015). Soleus and EDL muscle masses for OVX mice were 20 and 16% greater than for sham mice, respectively (Table 1) .
Total protein content was measured to determine if the muscle mass gains reflected an anabolic response or simply an increase in non-protein content, in response to ovariectomies.
Total protein content was not different between OVX and sham muscles (Table 1) . Furthermore, total protein concentration, i.e., total protein per muscle wet weight, was ~10% lower in muscles from OVX mice compared with sham mice (soleus muscle, 0.147 ± 0.009 vs. 0.162 ± 0.009 mg/mg; EDL muscle, 0.146 ± 0.012 vs. 0.163 ± 0.012 mg/mg; P 0.002).
Myosin and actin contents were measured to determine if the proportion of contractile to non-contractile protein was affected by the removal of ovarian hormones. Contractile protein content of soleus and EDL muscles was not different between OVX and sham mice (Table 1) and the ratio of myosin to actin was not different either (P 0.127). The mean (± SD) myosin and actin contents for all soleus muscles were 0.33 ± 0.05 and 0.16 ± 0.03 mg, respectively. The mean myosin and actin contents for all EDL muscles were 0.38 ± 0.06 and 0.18 ± 0.04 mg, respectively. The mean ratio of myosin to actin in soleus muscle was 1.52 and was 1.51 for EDL muscle. Thus the removal of ovarian hormones for 60 d did not alter the quantity of the major contractile proteins in hindlimb muscles of mice.
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Force generation
Soleus and EDL muscles from mice lacking ovarian hormones displayed lower forcegenerating capacity. P o of electrically-stimulated whole muscles from OVX mice was significantly lower than those from sham mice ( Figure 2 ). Because neither protein content or muscle length was different between OVX and sham mice (P 0.201), these data indicate that a qualitative difference in force generating capacity exists between muscles exposed to and deprived of ovarian hormones.
Maximal Ca 2+ -activated isometric force of permeabilized EDL fibers was measured during EPR experiments and was less in fibers from OVX mice than sham mice (3.71 ± 1.12 vs.
4.36 ± 0.77 mN P=0.042). Similarly, maximal Ca 2+ -activated force normalized to contractile protein content per fiber length was 25% less in fibers from OVX mice compared with those from sham mice (P = 0.043; Figure 2 ). Because the lower force in permeabilized fibers from OVX mice was similar in magnitude to the reduction in whole muscle force, these data indicate a qualitative difference between OVX and sham muscle in a contraction step occurring downstream of Ca 2+ release from the sarcoplasmic reticulum.
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To assess the possibility that actin-myosin interactions were altered by the removal of ovarian hormones, the structural distribution of myosin during contraction in EDL muscle fibers was measured. EPR spectroscopy showed that the fraction of strong-binding myosin during contraction was 15% less in EDL muscles from OVX mice compared with sham mice (0.277 ± 0.039 vs. 0.325 ± 0.020; P = 0.004; Figures 3 and 4) . Presently, EPR measurements of myosin strong-binding in soleus muscle fibers are not possible.
Another way to indirectly estimate the degree of myosin strong-binding during contraction is to measure active muscle stiffness. Active stiffness was determined on intact soleus and EDL muscles that were studied in vitro. Muscles from OVX mice had ~12% lower active stiffness than did muscles from sham mice (P 0.001; Table 2 and Figure 4 ). These data reinforce the EPR results showing that ovarian hormones qualitatively affected contractile protein function.
Passive stiffness, which reflects an inactive muscle's resistance to lengthening, was also determined for all soleus and EDL muscles studied in vitro. We found that passive stiffness of muscles from OVX mice was 12-20% greater than that from sham mice ( Table 2 ). The resistance to lengthening determined in passive stiffness measurements is due to elastic elements in parallel with force-generating elements suggesting that other structural elements in addition to contractile proteins are altered by removing ovarian hormones.
Maximal shortening velocity and peak power
Previous research on rodent skeletal muscle has shown shifts toward the expression of slower MHC isoforms following ovariectomy, leading to the hypothesis that contractile speed is affected by ovarian hormones (11) . To test this hypothesis maximum shortening velocity of Ovarian hormone effects on muscle contractility and myosin JAP-01029-2005.R1 14 intact soleus and EDL muscles was determined in vitro. V max normalized to muscle fiber length was 9% faster in soleus muscle from OVX mice compared with sham mice, but V max of EDL muscle was not different between groups (Table 2) . From the force-velocity experiment, peak muscle power generation was calculated. There were no differences in absolute peak power or peak power normalized to contractile protein content between muscles from OVX and sham mice ( Table 2 ).
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Discussion
The key finding of this study was that the loss of ovarian hormones for 60 d resulted in a reduced force-generating capacity for soleus and EDL muscles from mature female mice.
Contractile protein content of those muscles was not affected but Ca 2+ -activated force and the proportion of strong-binding myosin during contraction was reduced in fiber bundles from ovariectomized mice. The reduction in the fraction of strong-binding myosin occurred to the same extent as the decline in P o indicating that altered contractile protein function is a major mechanism underlying the force loss that is induced by removing ovarian hormones.
Mature, adult mice were used in this study, which is a key difference from previous muscle contractility studies on ovariectomized rodents (21, 27, 35). Our mice arrived at 5 mo of age and were fed a phytoestrogen-free diet to eliminate any potential influences of exogenous estrogen-like compounds, such as geinstein, that are common in many commercial rodent chows.
Mice were ovariectomized at 6 mo of age and muscle contractile function was assessed at ~8 mo of age. Previous muscle contractile studies were conducted on rodents that were ovariectomized between the ages of 6-10 wks (21, 35, 36), ages at which rodents are still growing and maturing and therefore better modeled amenorrheic adolescenct girls than menopausal women. Because a long-term goal of our studies is to distinguish age-from hormonally-related contractile losses, we used mature mice. However, we also did not want to confound our surgical intervention of ovariectomy with age-induced ovarian failure, so we selected the age of 8 mo as the end point of our studies to avoid approaching the age at which ovaries begin fail in mice, i.e., 11 to 16 months of age (4).
The greatest effect of removing ovarian hormones for 60 d was a decrease in forcegenerating capacity. We found ~18% lower P o 's normalized to contractile protein content per The dynamic molecular interaction of myosin binding strongly to actin generates force.
Thus, at the most elementary level, a loss of force results from 1) a decrease in the total number of myosin and actin molecules, 2) a decrease in the fraction of myosin molecules that are strongly bound to actin during the crossbridge cycle, and/or 3) a decrease in the force per strongly bound myosin molecule. We measured myosin and actin protein contents of soleus and EDL muscles and found that contents were not affected by the removal of ovarian hormones, ruling out possibility 1. Possibility 2 was directly measured by EPR spectroscopy, which revealed that the fraction of myosin heads strongly bound to actin during maximal isometric This result was substantiated by the active stiffness measurements made on intact muscles in vitro. According to Huxley's crossbridge model, stiffness of active muscle should be linearly related to the fraction of myosin heads strongly bound to actin (9) . Following this model, early calculations predicted that up to 80% of myosin heads were strongly attached to actin during isometric contraction (7). Later however, EPR spectroscopy, which directly measures the fraction of strong-binding myosin heads in functioning fibers during contraction, showed that the fraction was 20-30% for rabbit psoas fibers (3, 22) . Recently, active stiffness measurements have been used in conjunction with new values of filament compliance, and these calculations predict that the fraction of myosin heads attached to actin during isometric contraction can not be larger than 43% (18). Thus, direct measurement by spectroscopy and calculations based on active stiffness agree that that the fraction of myosin heads bound to actin during contraction is in the range of 30-40%, not 80% as initially predicted. In the present study we found that that difference in active stiffness between muscles from sham and OVX mice was ~12%, agreeing closely with the 15% difference determined by EPR (i.e., 33% vs. 27% strong-binding myosin).
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Thus, the removal of ovarian hormones for 60 d reduced the fraction of strong-binding myosin as determined both by EPR and active stiffness measurements on EDL muscles and by active stiffness measurements on soleus muscles. Again this ovariectomy-induced decrement in the proportion of strong-binding myosin can account for the entire reduction in P o for the OVX muscles.
Passive stiffness of soleus and EDL muscles was increased by 12-20% 60 d after ovarian hormone removal. Increased collagen content has been shown to increase passive stiffness (8) and could potentially have occurred in our study as a result of ovariectomy despite our finding that total protein content did not change. This is possible because our measure of total protein content does not reflect the contribution from collagen. Hence, if an increase in muscle collagen content occurred, it would be consistent with the observed increase in passive stiffness.
However, further investigation is needed to directly determine if ovarian hormones affect muscle collagen content.
In general, muscle maximal shortening velocity and peak power generation were minimally affected by ovariectomy. For EDL muscles there were no differences in V max or peak power between OVX and sham muscles. Soleus muscles became ~10% faster as a result of removing ovarian hormones, in agreement with a previous study showing faster muscle twitch kinetics in soleus muscles from immature ovariectomized rats (21). It is possible that there was a shift in MHC isoform expression in the soleus muscle which contributed to the muscle becoming faster. However this seems unlikely since previous studies have shown that the removal of ovarian hormones in rats had no effect on MHC isoform expression or caused a shift away from the faster IIa and IIb isoforms to the slower type I isoform (11, 21) . Soleus muscle peak power, a
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The levels of several hormones are altered when the ovaries are removed; therefore it is unclear which ovarian hormone(s) contributed to the contractile changes we observed. We speculate that the lack of estradiol, the most biologically active form of estrogen, is the key hormone responsible for the force decrements. The effects of estradiol are mediated through estrogen receptors which are located in the nucleus and act as transcription factors (12) . Gene expression is then regulated by the direct binding of estradiol-bound estrogen receptor to a specific sequence of DNA called the estrogen response element (13) . We predict that some muscle genes have estrogen response elements in their promoter regions and are thus regulated, at least in part, by estradiol. Thus, in the absence of estradiol it is possible that genes related to the regulation of myosin are perturbed resulting in altered myosin structure and force-generating function. Estrogen receptors are also located on the cell membrane but their function is not well defined (17) . Alternatively, the mechanism by which the loss of ovarian hormones leads to altered myosin may be related to estradiol's antioxidant property (12, 30) . For example, oxygen radical production after exercise-induced injury is low in mature female rats with normal estrogen levels suggesting that estrogen may offer a line of defense against free radicals (31).
Therefore, it is possible that a lowered anti-oxidant state occurs in the absence of estrogen leading to some post-translational oxidative modification at a critical site in myosin that in turn In summary, the present study shows that the loss of ovarian hormones for 60 days has detrimental effects on the force-generating capacities of mouse soleus and EDL muscles.
Furthermore, our data show that the decline in P o following the removal of ovarian hormones was not due to a reduction in contractile protein content but instead to a reduction in the fraction of strong-binding myosin during contraction. Additional research is needed to pin-point which ovarian hormone(s) is (are) critical in regulating muscle contractile function and myosin structure and to determine if those detrimental effects can be reversed. Values are means ± SD. P, P value from Student's independent t-test.
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Values are means ± SD. P t , peak twitch force; P o , maximal isometric tetanic force; V max , maximal shortening velocity per muscle fiber length; Normalized power, peak power per mg muscle contractile protein; P, P value from Student's independent t-test.
